These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 16367889

  • 21. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.
    Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S.
    J Intern Med; 2006 Aug; 260(2):125-33. PubMed ID: 16882276
    [Abstract] [Full Text] [Related]

  • 22. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [Abstract] [Full Text] [Related]

  • 23. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
    Derosa G, Cicero AF, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P.
    Diabet Med; 2013 Jul; 30(7):846-54. PubMed ID: 23413771
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS, Hershon PM.
    Endocr Pract; 2000 Jul; 6(1):20-5. PubMed ID: 11419922
    [Abstract] [Full Text] [Related]

  • 27. Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial.
    Chon S, Rhee SY, Ahn KJ, Baik SH, Park Y, Nam MS, Lee KW, Yoo SJ, Koh G, Lee DH, Kim YS, Woo JT, KIIT study investigators.
    Diabetes Obes Metab; 2018 May; 20(5):1121-1130. PubMed ID: 29272062
    [Abstract] [Full Text] [Related]

  • 28. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
    Bell DS, Ovalle F.
    Endocr Pract; 2000 May; 6(4):293-5. PubMed ID: 11242605
    [Abstract] [Full Text] [Related]

  • 29. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study.
    Musholt PB, Schöndorf T, Pfützner A, Hohberg C, Kleine I, Fuchs W, Hehenwarter S, Dikta G, Kerschgens B, Forst T.
    J Diabetes Sci Technol; 2009 Nov 01; 3(6):1442-50. PubMed ID: 20144400
    [Abstract] [Full Text] [Related]

  • 30. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O, Shaw JE, Blonde L, Paul SK.
    Diabetes Obes Metab; 2018 Jul 01; 20(7):1722-1731. PubMed ID: 29536608
    [Abstract] [Full Text] [Related]

  • 31. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
    Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, Barnett AH.
    Diabetes Obes Metab; 2014 May 01; 16(5):433-42. PubMed ID: 24237939
    [Abstract] [Full Text] [Related]

  • 32. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 May 01; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 33. Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes.
    Inagaki N, Watada H, Murai M, Kagimura T, Gong Y, Patel S, Woerle HJ.
    Diabetes Obes Metab; 2013 Sep 01; 15(9):833-43. PubMed ID: 23565760
    [Abstract] [Full Text] [Related]

  • 34. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
    Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.
    Diabetologia; 2005 Jun 01; 48(6):1093-104. PubMed ID: 15889234
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
    Schiel R, Müller UA.
    Exp Clin Endocrinol Diabetes; 2008 Jan 01; 116(1):58-64. PubMed ID: 17973208
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study.
    Dale J, Martin S, Gadsby R.
    Prim Care Diabetes; 2010 Jul 01; 4(2):85-9. PubMed ID: 20392683
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.